These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 30679233

  • 1. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.
    BMJ; 2019 Jan 24; 364():l67. PubMed ID: 30679233
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov 24; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 3. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
    Grøn KL, Arkema EV, Glintborg B, Mehnert F, Østergaard M, Dreyer L, Nørgaard M, Krogh NS, Askling J, Hetland ML, ARTIS Study Group.
    Ann Rheum Dis; 2019 Mar 24; 78(3):320-327. PubMed ID: 30612115
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 24; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 5. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 6. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
    Grøn KL, Glintborg B, Nørgaard M, Mehnert F, Østergaard M, Dreyer L, Krogh NS, Hetland ML.
    Rheumatology (Oxford); 2020 Aug 01; 59(8):1949-1956. PubMed ID: 31764977
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S, Aaltonen KJ, Viikinkoski J, Rutanen J, Relas H, Taimen K, Puolakka K, Nordström D, Blom M.
    PLoS One; 2019 Aug 01; 14(7):e0220142. PubMed ID: 31339961
    [Abstract] [Full Text] [Related]

  • 8. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S, Everett CC, Naraghi K, Davies C, Dawkins B, Hulme C, McCabe C, Pavitt S, Emery P, Sharples L, Buch MH.
    Health Technol Assess; 2018 Jun 01; 22(34):1-280. PubMed ID: 29900829
    [Abstract] [Full Text] [Related]

  • 9. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
    Salmon JH, Perotin JM, Morel J, Dramé M, Cantagrel A, Ziegler LE, Ravaud P, Sibilia J, Pane I, Mariette X, Gottenberg JE, French Society of Rheumatology.
    Rheumatology (Oxford); 2018 Jan 01; 57(1):134-139. PubMed ID: 29069471
    [Abstract] [Full Text] [Related]

  • 10. Safety profile of biological therapies for treating rheumatoid arthritis.
    Cañete JD, Hernández MV, Sanmartí R.
    Expert Opin Biol Ther; 2017 Sep 01; 17(9):1089-1103. PubMed ID: 28657381
    [Abstract] [Full Text] [Related]

  • 11. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV.
    Clin Ther; 2016 Dec 01; 38(12):2628-2641.e5. PubMed ID: 27889300
    [Abstract] [Full Text] [Related]

  • 12. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH, Bernasconi C, Aassi M, Molina JF, Epis OM.
    Arthritis Care Res (Hoboken); 2017 Oct 01; 69(10):1484-1494. PubMed ID: 28622454
    [Abstract] [Full Text] [Related]

  • 13. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
    Gülfe A, Wallman JK, Kristensen LE.
    Arthritis Res Ther; 2016 Feb 19; 18():51. PubMed ID: 26892115
    [Abstract] [Full Text] [Related]

  • 14. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
    Humby F, Durez P, Buch MH, Lewis MJ, Rizvi H, Rivellese F, Nerviani A, Giorli G, Mahto A, Montecucco C, Lauwerys B, Ng N, Ho P, Bombardieri M, Romão VC, Verschueren P, Kelly S, Sainaghi PP, Gendi N, Dasgupta B, Cauli A, Reynolds P, Cañete JD, Moots R, Taylor PC, Edwards CJ, Isaacs J, Sasieni P, Choy E, Pitzalis C, R4RA collaborative group.
    Lancet; 2021 Jan 23; 397(10271):305-317. PubMed ID: 33485455
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis.
    Elmedany SH, Mohamed AE, Galil SMA.
    Clin Rheumatol; 2019 Aug 23; 38(8):2109-2117. PubMed ID: 30915650
    [Abstract] [Full Text] [Related]

  • 16. Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.
    Prescrire Int; 2009 Oct 23; 18(103):198-201. PubMed ID: 19882783
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
    Choy E, Freemantle N, Proudfoot C, Chen CI, Pollissard L, Kuznik A, Van Hoogstraten H, Mangan E, Carita P, Huynh TM.
    RMD Open; 2019 Oct 23; 5(1):e000798. PubMed ID: 30886733
    [Abstract] [Full Text] [Related]

  • 18. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, Sarsour K, Schneeweiss S, Kim SC.
    Ann Rheum Dis; 2019 Apr 23; 78(4):456-464. PubMed ID: 30679153
    [Abstract] [Full Text] [Related]

  • 19. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
    Kim SC, Solomon DH, Rogers JR, Gale S, Klearman M, Sarsour K, Schneeweiss S.
    Semin Arthritis Rheum; 2018 Dec 23; 48(3):399-405. PubMed ID: 29673963
    [Abstract] [Full Text] [Related]

  • 20. Discontinuation of non-anti-TNF drugs for rheumatoid arthritis in interventional versus observational studies: a systematic review and meta-analysis.
    Tonin FS, Steimbach LM, Leonart LP, Ferreira VL, Borba HH, Piazza T, Araújo AG, Fernandez-Llimos F, Pontarolo R, Wiens A.
    Eur J Clin Pharmacol; 2018 Nov 23; 74(11):1513-1521. PubMed ID: 30022333
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.